Onesource Specialty Pharma Limited · NSE:ONESOURCE

Onesource Specialty Pharma — Q3 FY25 Earnings Presentation

18 slides from Onesource Specialty Pharma's earnings presentation, Jan 29, 2025

  1. Slide 1: Stock exchange cover letter: Press Release

    Corporate Office: Registered Office: Star 1, Opp IIM Bangalore, Bilekahalli, 201, Devavrata, Sector 17, Vashi, Bannergha a Road, Bengaluru – Navi Mumbai - 400 703, India 560076, India T: +91 22 2789 2924 T: +91 80 6784 0738 F: +91 22 2789 2942 Date: 29.01.2025 BSE Limited National Stock Exchange of Indi

  2. Slide 2: OneSource announces strong financial results in its first quarter post-listing

    Press Release January 29, 2025 OneSource announces strong financial results in its first quarter post- listing; Q3FY25 revenues at ₹3,926 million with an EBITDA of ₹1,432 million, demonstrating a 36.5% EBITDA margin Q3FY25 Performance Highlights • Revenues of ₹3,926 million grew 18% QoQ. • EBITDA gr

  3. Slide 3: For further information, please contact

    Press Release January 29, 2025 For further information, please contact: Institutional Investors Corporate Communication Anurag Bhagania Pallavi Panchmatia: +91 8951939181 CFO Abhilash Mukherjee: +91 89044 28907 Email: investor- Email: corpcomm@onesourcecdmo.com relations@onesourcecdmo.com PR Consult

  4. Slide 4: The New Way to CDMO: Q3'25 earnings update

    THE NEW WAY TO CDMO earnings Q3’25 update OneSource Specialty Pharma Ltd | January 29, 2025

  5. Slide 5: Safe harbor

    Safe harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "p

  6. Slide 6: Quarterly Highlights Q3'25

    Quarterly Highlights Q3’25 2

  7. Slide 7: A stellar debut in its first quarter as an independent platform

    A stellar debut in its first quarter as an independent platform: Strong Q3 results and significant new business wins across modalities have set the stage for continued growth and profitability ( Q3’25 Key Financial Highlights ) We're off to a promising start as an independent platform. Our strong Q3

  8. Slide 8: Strong Q3 Performance with normalized PAT of ₹898 million

    Strong Q3 Performance with normalized PAT of ₹898 million Particulars (In ₹ million) Reported Normalized Remarks EBITDA 1,432 1,432 • EBITDA margins at 36% Other income 54 54 • Interest income, Forex gain Finance cost - Continued debt (232) (232) • Recurring cost of ₹232m continuing debt Finance cos

  9. Slide 9: Delivering continued upward trajectory

    Delivering continued upward trajectory: Onesource continues building on its successful project delivery track record and a strong pipeline of ongoing projects 60+ Global customers 54 78 million 20 GLP-1 customers Successful regulatory, customer audits in last 2 years Industry leading DDC capacity (4

  10. Slide 10: Meeting the FY25 targets

    Meeting the FY25 targets : On track for a strong finish to FY25, laying the groundwork for continued and accelerated growth in the future Particulars FY25 Outlook($m) FY25 Outlook(₹m) Status o On Sep 26, 2024, Onesource updated an investor presentation via the Strides website: [Link] Revenues $160-$

  11. Slide 11: Investing into the future: Capex of $100m over 4 years

    Investing into the future: Capex of $100m over 4 years to build capacities and unparalleled CDMO capabilities Capacity FY25 FY26 FY27 FY28 Cartridges 40 100 140 220 (Million units) Pre-filled syringe 38 38 38 38 (Million units) 2.4 billion annual capacity is available as part of the transition servi

  12. Slide 12: Outlook: OneSource creation is now complete

    Outlook: Onesource creation is now complete, and we're unlocking our full potential to drive superior financial performance and deliver exceptional value to our stakeholders ( Targeted Key Metrics ) H2’25E 3–4-year Key metrics Annualized2 outlook o Capital Investments secured: Adequately funded to f

  13. Slide 13: About OneSource

    about nesource

  14. Slide 14: Our business at a glance

    India’s first Specialty Pharma CDMO covering Biologics, Drug-device combinations, complex Injectables and Oral Technologies (soft gelatin capsules) 5 state-of-the-art facilities with approval from major regulatory agencies, with 54 successful inspections in last 24 months 1,200+ employees with 100+

  15. Slide 15: Diverse, multi-modality approach with a comprehensive suite of services

    OneSource stands out among global CDMOs by offering a diverse, multi-modality approach with a comprehensive suite of services Drug-device Combinations Biologics Soft gelatin Sterile fill-finish including GLP-1s (DS and DP) capsules1 (excluding DDCs) ~14% CAGR: % R: ~9 % CAG R: ~5 CAG R: >20% CDMO Ma

  16. Slide 16: Deep expertise, extensive installed capacity, and proven compliance track record

    OneSource's deep expertise in development, extensive installed capacity, and proven compliance track record ensure high-quality, reliable service for our clients Formulation capabilities – 35+ approved ANDAs for Sterile Injectables Scale advantage – Installed capacities and soft gelatin capsules acr

  17. Slide 17: Poised for sustained growth driven by industry opportunities and M&A trends

    Poised for sustained growth over the coming decades, driven by conducive industry opportunities and M&A trends M&A in CDMO space GLP-1s rise Supply Chain diversification Acquisition of a large CDMO Obesity and Diabetes are major societal challenges à Global biopharmaceuticals looking for alternative

  18. Slide 18: Get in touch with us

    the new way to CDMO Get in touch with us REGISTERED AND CORPORATE OFFICE INVESTOR RELATIONS OneSource Specialty Pharma Ltd investors@onesourcecdmo.com Registered Office: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India T: +91 22 2789 2924 F: +91 22 2789 2942 Corporate Office: OneSource

OneSource Specialty Pharma — Q3 FY25 Earnings Presentation on 6ix